Valuation: Pulmonx Corporation

Market Cap 88.9M 77.52M 73.2M 66.47M 125M 8.53B 125M 877M 338M 4.34B 334M 327M 13.96B P/E 2026 *
-1.98x
P/E 2027 * -2.2x
Enterprise Value 88.9M 77.52M 73.2M 66.47M 125M 8.53B 125M 877M 338M 4.34B 334M 327M 13.96B EV / Sales 2026 *
0.98x
EV / Sales 2027 * 0.9x
Free-Float
95.36%
Yield 2026 *
-
Yield 2027 * -
1 day+4.55%
1 week+11.89%
Current month-13.03%
1 month-8.41%
3 months+61.72%
6 months+39.86%
Current year-6.33%
1 week 1.83
Extreme 1.83
2.08
1 month 1.82
Extreme 1.815
2.59
Current year 1.13
Extreme 1.13
2.59
1 year 1.13
Extreme 1.13
2.89
3 years 1.13
Extreme 1.13
14.84
5 years 1.13
Extreme 1.13
45.49
10 years 1.13
Extreme 1.13
69.48
Manager TitleAgeSince
Chief Executive Officer 64 26/10/2025
Director of Finance/CFO 53 30/04/2019
Chief Tech/Sci/R&D Officer - 29/02/2020
Director TitleAgeSince
Director/Board Member 72 31/01/2007
Chairman 66 30/09/2019
Director/Board Member 64 17/12/2014
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Sell

Chief Technology Officer

-14,245 0.0332%
01/09/26 Sell

Chief Executive Officer

-41,882 0.0975%
01/09/26 Sell

Executive/Senior Manager

-7,879 0.0183%
Change 5-day change 1-year change 3-year change Capi.($)
+4.55%+11.89%+29.38%-80.40% 85.04M
-0.40%-0.04%+23.22%+21.11% 12.56B
-1.05%+0.77%+11.94%+16.93% 6.62B
-1.09%-3.16% - - 6.2B
-0.21%+2.66%+23.70%+10.27% 5.59B
-1.53%-1.17%-20.99%+35.65% 5.06B
+0.38%+3.39%-31.74%-24.86% 3.88B
-0.18%+7.61%+28.38%-11.32% 1.95B
-1.65%-2.30%-18.13%+191.44% 1.75B
-1.95%+2.06%+45.86%-17.74% 1.61B
Average -0.31%+1.93%+10.18%+15.68% 4.53B
Weighted average by Cap. -0.71%+0.15%+9.56%+20.35%

Financials

2026 *2027 *
Net sales 90.55M 78.96M 74.55M 67.7M 127M 8.69B 127M 893M 345M 4.42B 340M 333M 14.21B 98.31M 85.73M 80.95M 73.51M 138M 9.43B 138M 970M 374M 4.8B 369M 361M 15.43B
Net income -44.24M -38.57M -36.42M -33.07M -61.97M -4.24B -62.23M -436M -168M -2.16B -166M -162M -6.94B -40.71M -35.5M -33.52M -30.44M -57.03M -3.91B -57.27M -402M -155M -1.99B -153M -150M -6.39B
Net Debt - -
Logo Pulmonx Corporation
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Employees
296
Date Price Change Volume
18/09/26 US$2.070 +4.55% 430,059
17/09/26 US$1.980 +1.54% 264,027
16/09/26 US$1.950 +2.09% 232,470
15/09/26 US$1.910 -3.05% 228,930
14/09/26 US$1.970 +6.49% 292,854
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.070USD
Average target price
3.400USD
Spread / Average Target
+64.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LUNG Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!